Home
This Title All WIREs
WIREs RSS Feed
How to cite this WIREs title:
WIREs Nanomed Nanobiotechnol
Impact Factor: 6.14

Targeted nanoparticles for head and neck cancers: overview and perspectives

Full article on Wiley Online Library:   HTML PDF

Can't access this content? Tell your librarian.

Head and neck cancer (HNC) is common in several regions and is associated with high morbidity and mortality worldwide. This review summarizes the recent progress in the development of targeted nanoparticle systems for HNC therapy. WIREs Nanomed Nanobiotechnol 2017, 9:e1469. doi: 10.1002/wnan.1469 This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease
Head and neck cancer statistics worldwide.
[ Normal View | Magnified View ]
The past, present and future of the treatment of head and neck cancer. Past, work includes (a) examining the tumor site and identifying the mode of operation based on TNM staging; (b) surgery to remove the tumor; and (c) use of radiotherapy as adjuvant treatment. Present, on‐going treatment consists of (a) examining the tumor site and establishing the operation plan; (b) combining radiotherapy and chemotherapy as adjuvant therapies. Future, promising strategies include (a) combining more kinds of treating strategies to optimize the efficiency; (b) employing targeted nanoparticles to deliver the drug in order to improve drug efficiency and decrease off‐target effects.
[ Normal View | Magnified View ]
Illustration of the cSLN nanoparticles loaded with paclitaxel and siRNA. EcSLN (a) and PcSLN (b) were used as co‐delivery system of lipophilic anticancer drug and therapeutic siRNAs.
[ Normal View | Magnified View ]
pH‐sensitive poly 2‐(methacryloyloxy) ethyl phosphorylcholine (PMPC)‐ poly 2‐(diisopropylamino) ethyl methacrylate (PDPA) polymersomes used as drug delivery vehicles for effective combinational anticancer therapy.
[ Normal View | Magnified View ]
Schematic illustration of the preparation of water‐soluble FMP‐IO‐PC4 nanoparticles which can serve as both a MRI agent and PDT drug.
[ Normal View | Magnified View ]
Nanotube‐based delivery system. (a) Illustration of modified the carboxylated SWNTs (in green) surface with EGF, cisplatin, and Qdots. (b) Schematic presenting the SWNT bundles bioconjugated with EGF and cisplatin recognized by the receptor EGFR on a HNSCC cell surface.
[ Normal View | Magnified View ]
Illustration of nanoparticles modified with targeted groups. EGFR vIIIAb was attached on surface of Amphiphilic block polymer nanoparticles for specific targeting to the tumor site.
[ Normal View | Magnified View ]
Illustration of adjuvant therapy of HNC. Radiotherapy was the standard treatment care for resectable HNC. While now cisplatin plus radiotherapy is the mainstay of HNC. Docetaxel, cisplatin plus 5‐fluorouracil (TPF) is the standard regimen for induction chemotherapy. Cetuximab/lapatinib is the monoclonal antibody against the ligand binding domain of EGFR.
[ Normal View | Magnified View ]
Anatomic subsites of some common primary sites of HNC.
[ Normal View | Magnified View ]

Browse by Topic

Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease

Access to this WIREs title is by subscription only.

Recommend to Your
Librarian Now!

The latest WIREs articles in your inbox

Sign Up for Article Alerts